Lys525
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.1
Powered by Cell Signaling Technology
Home > Ubiquitylation Site Page: > Lys525  -  Ku80 (human)

Site Information
PPAEVttksQIPLsk   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 12348116

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 2 ) , immunoprecipitation ( 2 ) , mass spectrometry ( 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 ) , mutation of modification site ( 2 ) , western blotting ( 2 )
Disease tissue studied:
bone cancer ( 2 ) , leukemia ( 9 ) , acute lymphocytic leukemia ( 9 ) , lung cancer ( 2 ) , non-small cell lung cancer ( 2 ) , multiple myeloma ( 6 , 7 , 8 )
Relevant cell line - cell type - tissue:

Downstream Regulation
Effects of modification on Ku80:
molecular association, regulation ( 2 )
Effects of modification on biological processes:
DNA repair, induced ( 2 )
Inhibit interaction with:
DNA ( 2 )

References 

1

Lumpkin RJ, et al. (2017) Site-specific identification and quantitation of endogenous SUMO modifications under native conditions. Nat Commun 8, 1171
29079793   Curated Info

2

Ishida N, et al. (2017) Ubiquitylation of Ku80 by RNF126 Promotes Completion of Nonhomologous End Joining-Mediated DNA Repair. Mol Cell Biol 37
27895153   Curated Info

3

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

4

Udeshi ND, et al. (2013) Refined preparation and use of anti-diglycine remnant (K-ε-GG) antibody enables routine quantification of 10,000s of ubiquitination sites in single proteomics experiments. Mol Cell Proteomics 12, 825-31
23266961   Curated Info

5

Kim W, et al. (2011) Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell 44, 325-40
21906983   Curated Info

6

Guo A (2010) CST Curation Set: 10264; Year: 2010; Biosample/Treatment: cell line, U266/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

7

Guo A (2010) CST Curation Set: 10265; Year: 2010; Biosample/Treatment: cell line, U266/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

8

Guo A (2010) CST Curation Set: 9914; Year: 2010; Biosample/Treatment: cell line, AMO-1/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

9

Guo A (2010) CST Curation Set: 9186; Year: 2010; Biosample/Treatment: cell line, Reh/untreated; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

10

Guo A (2009) CST Curation Set: 8646; Year: 2009; Biosample/Treatment: cell line, U266/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info